© 2018

Myelodysplastic Syndromes

Diagnosis - Prognosis - Therapy

  • Uwe Platzbecker
  • Pierre Fenaux

Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Table of contents

  1. Front Matter
    Pages i-v
  2. Diagnostics and Prognosis

    1. Front Matter
      Pages 1-1
    2. Katja Sockel, Frank Kroschinsky, Uta Oelschlaegel, Arjan A. van de Loosdrecht
      Pages 3-13
    3. Austin G. Kulasekararaj, Olivier Kosmider, Ghulam J. Mufti
      Pages 15-37
    4. Stefan Dirnhofer
      Pages 39-41
    5. Detlef Haase, Charikleia Kelaidi
      Pages 43-64
    6. Matthieu Duchmann, Nolwenn Lucas, Raphael Itzykson, Eric Solary
      Pages 65-79
  3. Therapy

    1. Front Matter
      Pages 81-81
    2. S. Park, K. Götze
      Pages 83-95
    3. Anna Mies, Amit Verma, Uwe Platzbecker
      Pages 97-104
    4. Norbert Gattermann, Christian Rose
      Pages 105-118
    5. Aristoteles Giagounidis, Lionel Adès
      Pages 119-129
    6. Ulrich Germing, Pierre Fenaux
      Pages 131-139
    7. Bart L. Scott, M. Robin
      Pages 141-157

About this book


This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation.

Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.


Myelodysplastic Syndromes Anemia Erythropoietic Stimulating Agents Hypomethylating Agents Iron Chelation Therapy

Editors and affiliations

  • Uwe Platzbecker
    • 1
  • Pierre Fenaux
    • 2
  1. 1.Medizinische Klinik und Poliklinik 1Universitätsklinikum Dresden Medizinische Klinik und Poliklinik 1DresdenGermany
  2. 2.Department of HematologyHospital Saint LouisParisFrance

About the editors

Uwe Platzbecker graduated from medical school in 1996 and then trained in heart surgery. Since 1998 he has worked in the Department of Hematology and Oncology at the University Hospital “Carl Gustav Carus” in Dresden, Germany. Between 2001 and 2003 he completed a 2-year postdoctoral fellowship provided by the Humboldt Foundation at the Fred Hutchinson Cancer Research Center in Seattle, USA. Since 2012, he has held the position of Professor of Hematology at the University Hospital “Carl Gustav Carus” and is head of the MDS program there. Professor Platzbecker`s clinical expertise lies in hematological malignancies with a focus on MDS and AML. His main scientific interest is innovative treatment options for these patients involving the use of allogeneic hematopoietic stem cell transplantation. He is the author of numerous papers, book chapters, and abstracts. Professor Platzbecker is also co-chair of the EHA MDS working group. In 2012 he was appointed by the ELN MDS group as one of the coordinators of the European MDS Study Coordinating Office (EMSCO).

Pierre Fenaux trained at the University Hospital of Lille, France, where he became Professor in Hematology in 1993. Between 2002 and 2013 he founded and was head of the clinical hematology section at Hôpital Avicenne, Paris 13 University. He then moved to Hôpital St Louis, Paris 7 University to create a new clinical hematology section for myeloid disorders in the elderly, which he currently chairs. He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (especially promyelocytic leukemia). He is a founding member and chairman of the French-speaking MDS group (Groupe Francophone des Myélodysplasies) and of the French APL group (GT-LAP). He is also a member of the board of directors of the MDS Foundation. He is the author of numerous scientific articles in peer-reviewed journals.

Bibliographic information

  • Book Title Myelodysplastic Syndromes
  • Book Subtitle Diagnosis - Prognosis - Therapy
  • Editors Uwe Platzbecker
    Pierre Fenaux
  • Series Title Hematologic Malignancies
  • Series Abbreviated Title Hematologic Malignancies
  • DOI
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-3-319-76878-6
  • Softcover ISBN 978-3-030-08316-8
  • eBook ISBN 978-3-319-76879-3
  • Series ISSN 2197-9766
  • Series E-ISSN 2197-9774
  • Edition Number 1
  • Number of Pages V, 157
  • Number of Illustrations 4 b/w illustrations, 22 illustrations in colour
  • Topics Hematology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology


“This is an up‐to‐date review of the diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS). In light of the recent advances in this field, the book makes a laudable effort to highlight the importance of prognostic stratification and discusses in depth both standard therapeutic practices and novel approaches. … At barely 150 pages, this comprehensive yet succinct book is an excellent resource on MDS that is very informative, authoritative, and easy to read.” (Ravi Salgia, Doody's Book Reviews, December 14, 2018)